Co-Diagnostics, Inc. has announced a reverse stock split of its common stock, effective November 24, 2026. This decision, approved by the company's board and stockholders, aims to enhance the stock's market price and attract institutional investors. The reverse split will consolidate every 25 shares into one share, a strategic move that reflects ongoing efforts to optimize the company's capital structure.
Co-Diagnostics, based in Salt Lake City, Utah, operates in the Surgical & Medical Instruments & Apparatus sector, as classified under the Standard Industrial Classification (SIC) code 3841. The company trades on the Nasdaq under the ticker symbol CODX. This recent filing is part of a series of updates from the company, including its latest quarterly results and other operational disclosures.
According to the filing dated November 19, 2026, the reverse stock split was approved during a special meeting of stockholders on November 13, 2026. The board of directors has set a split ratio of 1-for-25, which will be effective at 12:01 a.m. Mountain Time on November 24, 2026. Following this, shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market.
The filing states, "As a result of the reverse stock split, every 25 shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one (1) issued and outstanding share of common stock." The company will not issue fractional shares; instead, stockholders entitled to a fraction will receive one whole share. Importantly, this move will not alter the rights or preferences of the common stock or the number of shares authorized for issuance.
Post-split, approximately 521,779 shares of common stock will be outstanding, with the shares continuing to trade under the symbol CODX but with a new CUSIP number. All outstanding stock options and warrants will also be proportionally adjusted in accordance with their terms.
The reverse stock split is expected to affect current shareholders, institutional investors, and potential investors looking at Co-Diagnostics as a viable option in the medical instruments market. The company has appointed VStock Transfer, LLC, as the exchange agent for the reverse stock split, ensuring a smooth transition for shareholders.
Looking ahead, the company has not specified any further actions or filings following this announcement. The filing does not say what happens next, leaving stakeholders to await further updates from the company.
Read Next
Broadwood Partners Acquires 3.4 Million Shares of Insight Molecular
Arrive AI Inc. Converts Debt to Equity in Strategic Exchange
Granite Ridge Resources to Distribute 14M Shares to Grey Rock
LKQ Corporation Board Transition: Metcalf Steps Down, Waltz Joins
SFS Holding's Mat Ishbia Acquires Over 39 Million Warrants
Federal Home Loan Bank of Dallas Issues New Consolidated Obligations










